During March 2018, RayStation was selected as treatment planning system for Emory Proton Therapy Center, owned and operated by Provident Resources Group Inc. The new facility is currently under construction in Atlanta, Georgia, and is scheduled to treat its first patients in late 2018. Motivating factors for the choice include advanced functionality such as Monte Carlo dose optimization, 4D optimization, and multi-criteria robust optimization.
The comprehensive RayStation installation includes VMAT, pencil beam scanning, multi-criteria optimization, biological optimization, fallback planning, deformable registration, dose tracking, adaptive replanning and contouring. The majority of this order has been delivered and generated revenue in the first quarter of 2018. The order was also part of the announcement on March 31, 2018, read more here.
When operational, Emory Proton Therapy Center and its clinical partners, The Emory Clinic and Emory Healthcare, will have the capacity to treat approximately 1800 patients per year, in five treatment rooms equipped with Varian’s ProBeam proton system. The technology on hand will include pencil beam scanning and intensity modulated proton therapy, as well as a robotic positioning system and advanced imaging technology such as on-gantry cone beam CT volumetric imaging. The center will also be an international leader in proton therapy research.
Mark McDonald, Medical Director, Emory Proton Therapy Center, says: “Our team selected RayStation because of its advanced treatment planning functions relevant to proton therapy, including Monte Carlo dose optimization, 4D optimization, and multi-criteria optimization. We believe these features are critical to the development of high-quality and safe treatment plans that can extend the advantages of proton therapy to patients with a wider array of diagnoses. We look forward to continued collaboration with RaySearch as an excellent and innovative partner in proton treatment planning.”
Johan Löf, CEO of RaySearch, says: “The leading functionality of RayStation is a very good match for Emory Proton Therapy Center, which will be a pioneering center for proton therapy and clinical research. Proton therapy is a key focus area for RaySearch, and we are constantly evolving our capabilities to include advanced features, such as Monte Carlo, to meet the needs of world leading centers. We are confident of a successful collaboration that will benefit many patients in Georgia.”
About Emory Proton Therapy Center
The Emory Proton Therapy Center combines the world’s most advanced radiation technologies and treatment with the expertise of renowned specialists from Winship Cancer Institute of Emory University, Georgia’s National Cancer Institute-designated comprehensive cancer center. When it opens in late 2018, the Emory Proton Therapy Center will be the first center of its kind in Georgia and one of only a few in the southeast US to offer patients access to this leading-edge type of radiation therapy. Winship Cancer Institute is at the forefront of cancer research and discovery, developing and delivering some of the world’s most effective ways to prevent, detect, diagnose, and treat cancer.
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
To learn more about RaySearch, go to: www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00